Crossmark

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Crossref DOI link: https://doi.org/10.1038/s41596-021-00536-y

Published Online: 2021-04-23

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bewley, Kevin R. https://orcid.org/0000-0002-9078-6734
Coombes, Naomi S. https://orcid.org/0000-0001-9631-6875
Gagnon, Luc

McInroy, Lorna

Baker, Natalie

Shaik, Imam

St-Jean, Julien R.

St-Amant, Natalie

Buttigieg, Karen R.

Humphries, Holly E.

Godwin, Kerry J.

Brunt, Emily

Allen, Lauren

Leung, Stephanie

Brown, Phillip J. https://orcid.org/0000-0001-6367-6495
Penn, Elizabeth J.

Thomas, Kelly https://orcid.org/0000-0002-0348-654X
Kulnis, Greg

Hallis, Bassam

Carroll, Miles

Funnell, Simon https://orcid.org/0000-0002-4254-2751
Charlton, Sue
Funding

Funding for this research was provided by:

The PNA elements of this work were supported by the Global Health Vaccine Accelerator Platforms (GH-VAP) and the Coronavirus Immunotherapy Consortium (CoVIC) funded by BMGF
License Information

Text and Data Mining valid from 2021-04-23

Version of Record valid from 2021-04-23
More Information

Article History

Received: 7 December 2020

Accepted: 17 March 2021

First Online: 23 April 2021

Competing interests

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below